Physician profile
Nathali Eiranova
NPI 1689204729
$5,554.21
in general payments reported to CMS, 2019-2025
27 companies · $1,539 in 2025
The $1,539 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $546 · 2022: $427 · 2023: $2,340 · 2024: $701 · 2025: $1,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,086 · Consulting Fee: $1,350 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,086.07 |
| Consulting Fee | $1,350.00 |
| Education | $144.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $1,215.96 | 2023-2025 | Zoryve |
| Almirall LLC | $629.21 | 2023 | Seysara, Klisyri |
| E.R. Squibb & Sons, L.L.C. | $613.68 | 2023-2025 | Sotyktu |
| Incyte Corporation | $593.62 | 2023-2025 | Opzelura, Opzelura |
| Abbvie INC. | $546.61 | 2021-2024 | |
| Amgen INC. | $447.70 | 2022-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $310.35 | 2022-2025 | Winlevi, Absorica Ld |
| Pfizer INC. | $195.38 | 2021-2023 | |
| Journey Medical Corporation | $170.38 | 2025 | |
| Galderma Laboratories, L.P. | $149.76 | 2023-2025 | Aklief |
| Amarin Pharma, INC. | $109.75 | 2021 | |
| Novartis Pharmaceuticals Corporation | $101.06 | 2023-2025 | |
| Novo Nordisk INC | $56.28 | 2021 | |
| Revance Therapeutics, INC. | $52.57 | 2024 | Daxxify |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.49 | 2023-2024 | Jublia, Arazlo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $45.47 | 2021 | |
| Lnhc, INC | $45.34 | 2025 | Zelsuvmi |
| Lilly USA, LLC | $43.09 | 2021-2024 | Olumiant |
| Jazz Pharmaceuticals INC. | $39.76 | 2021 | |
| Leo Pharma INC. | $21.24 | 2025 | Anzupgo |
| Organon LLC | $19.72 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $18.69 | 2022 | |
| Clarus Therapeutics INC. | $18.46 | 2021 | |
| Acerus Pharmaceuticals Corporation | $18.08 | 2021 | |
| Mayne Pharma Commercial LLC | $17.58 | 2023 | |
| Merck Sharp & Dohme LLC | $13.55 | 2021 | |
| Esperion Therapeutics, INC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathali Eiranova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.